A Clinical Trial With Influenza A/H1N1 Vaccines
This study has been completed.
Sponsor:
Sinovac Biotech Co., Ltd
Information provided by:
Sinovac Biotech Co., Ltd
ClinicalTrials.gov Identifier:
NCT00956111
First received: August 10, 2009
Last updated: October 28, 2009
Last verified: October 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
A single center, stratified, randomized and double-blind phase IV clinical trial is to be conducted in healthy elders (equal to or more than 61 years), adults (18-60 years), adolescents (12-17 years) and children (3-11 years) to evaluate the safety and immunogenicity of Sinovac's split-virion or whole-virion novel influenza A (H1N1) vaccines.
| Condition | Intervention | Phase |
|---|---|---|
|
Influenza |
Biological: split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose Biological: split-virion, adjuvanted H1N1 vaccine of 15 μg per dose Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose Biological: whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose Biological: whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose Biological: placebo control |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | A Double-blind, Randomized, Stratified and Controlled Clinical Trial With Split-virion and Whole-virion, Adjuvanted and Non-adjuvanted Influenza A/H1N1 Vaccines in Healthy Adults, Elders, Adolescents and Children |
Resource links provided by NLM:
MedlinePlus related topics:
Flu
Drug Information available for:
Influenza Vaccines
U.S. FDA Resources
Further study details as provided by Sinovac Biotech Co., Ltd:
Primary Outcome Measures:
- Evaluate immunogenicity and safety of influenza A (H1N1)vaccines in elders, adults, adolescent and children . [ Time Frame: July 2009- Sept. 2009 ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Provide a basis to determine the best type and dose of vaccine and immunization procedures [ Time Frame: July 2009- Sept. 2009 ] [ Designated as safety issue: No ]
| Enrollment: | 1614 |
| Study Start Date: | July 2009 |
| Study Completion Date: | October 2009 |
| Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg
300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
|
Biological: split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose
100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
|
|
Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg
300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
|
Biological: split-virion, adjuvanted H1N1 vaccine of 15 μg per dose
100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
|
|
Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
|
Biological: split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose
100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
|
|
Experimental: split-virion, non-adjuvanted H1N1 vaccine of 30 μg
300 participants (100 adults, 100 adolescents and 100 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
|
Biological: split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose
100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
|
|
Experimental: whole-virion, adjuvanted H1N1 vaccine of 5 μg
100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 5 μg on day 0 and 21.
|
Biological: whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose
100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.
|
|
Experimental: whole-virion, adjuvanted H1N1 vaccine of 10 μg
200 participants: 100 adults to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 and 21. 100 elders to receive whole-virion, adjuvanted H1N1 vaccine of 10 μg on day 0 only. |
Biological: whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose
100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
|
|
Placebo Comparator: Placebo control
100 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
|
Biological: placebo control
100 adults were assigned to receive 2 doses of placebo 21 days apart.
|
Eligibility| Ages Eligible for Study: | 3 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy male or female aged 3 and older
- Be able to show legal identity card for the sake of recruitment
- Volunteers or their guardians are able to understand and sign the informed consent
Exclusion Criteria:
- Cases, cured cases and close contact of influenza A (H1N1) virus
- Women of pregnancy, lactation or about to be pregnant in 60 days
- Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine, such as egg, egg protein, etc
- Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
- Autoimmune disease or immunodeficiency
- Asthma that is unstable or required emergent care, hospitalization or intubation during the past two years or that required the use of oral or intravenous corticosteroids
- Diabetes mellitus (type I or II), with the exception of gestational diabetes
- History of thyroidectomy or thyroid disease that required medication within the past 12 months
- Serious angioedema episodes within the previous 3 years or requiring medication in the previous two years
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- Active malignancy or treated malignancy for which there is not reasonable assurance of sustained cure or malignancy that is likely to recur during the period of study
Seizure disorder other than:
- Febrile seizures under the age of two years old
- Seizures secondary to alcohol withdrawal more than 3 years ago, or
- A singular seizure not requiring treatment within the last 3 years
- Asplenia, functional asplenia or any condition resulting in the absence or removal o the spleen
- Guillain-Barre Syndrome
- Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- History of any blood products or seasonal influenza vaccine administration within 3 months before the dosing
- Administration of any other investigational research agents within 30 days before the dosing
- Administration of any live attenuated vaccine within 30 days before the dosing
- Administration of subunit or inactivated vaccines, e.g., pneumococcal vaccine, or allergy treatment with antigen injections, within 14 days before the dosing
- Be receiving anti-TB prophylaxis or therapy currently
- Axillary temperature > 37.0 centigrade at the time of dosing
Psychiatric condition that precludes compliance with the protocol:
- Past or present psychoses
- Past or present bipolar disorder requiring therapy that has not been well controlled on medication for the past two years
- Disorder requiring lithium
- Suicidal ideation occurring within five years prior to enrollment
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Contacts and Locations
More Information
No publications provided by Sinovac Biotech Co., Ltd
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Wei-Dong Yin, Sinovac Biotech Co., Ltd |
| ClinicalTrials.gov Identifier: | NCT00956111 History of Changes |
| Other Study ID Numbers: | PRO-PanFlu-4001 |
| Study First Received: | August 10, 2009 |
| Last Updated: | October 28, 2009 |
| Health Authority: | China: Food and Drug Administration |
Keywords provided by Sinovac Biotech Co., Ltd:
|
Novel Influenza A/H1N1 Vaccine Immunogenictiy Safety |
Additional relevant MeSH terms:
|
Influenza, Human Orthomyxoviridae Infections RNA Virus Infections |
Virus Diseases Respiratory Tract Infections Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on June 13, 2013